U.S. markets close in 5 hours 3 minutes
  • S&P 500

    4,449.46
    -6.02 (-0.14%)
     
  • Dow 30

    34,957.22
    +159.22 (+0.46%)
     
  • Nasdaq

    14,969.73
    -77.97 (-0.52%)
     
  • Russell 2000

    2,279.98
    +31.91 (+1.42%)
     
  • Crude Oil

    75.15
    +1.17 (+1.58%)
     
  • Gold

    1,751.40
    -0.30 (-0.02%)
     
  • Silver

    22.68
    +0.26 (+1.14%)
     
  • EUR/USD

    1.1707
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    1.4850
    +0.0250 (+1.71%)
     
  • GBP/USD

    1.3707
    +0.0026 (+0.19%)
     
  • USD/JPY

    110.9440
    +0.2590 (+0.23%)
     
  • BTC-USD

    43,198.93
    -137.86 (-0.32%)
     
  • CMC Crypto 200

    1,075.59
    -25.93 (-2.35%)
     
  • FTSE 100

    7,068.25
    +16.77 (+0.24%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Abeona Therapeutics Inc (NASDAQ: ABEO) has announced updated data from Phase 1/2a trial for up to six years following treatment with EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).

  • The data showed that investigator assessment of wound healing of over 50% from baseline was present in 69% of treated wounds (n=18/26) at three years, 93% (n=14/15) at four years, 80% (n=12/15) at five years, and 80% (n=4/5) at six years.

  • The results were shared at the Society for Pediatric Dermatology (SPD) 46th Annual Meeting.

  • The data also showed that pain was absent in all treated wounds that were evaluated at three years (n=26), four years (n=15), five years (n=15), and six years (n=5) of follow up, compared with the presence of pain at baseline in 53% (n=20/38) of treated wounds.

  • A separate survey data showed that 76% of the treated wounds with 50% or greater healing were associated with improved pain scores, with 53% associated with "much/very much improved" pain scores.

  • EB-101 is an autologous, gene-corrected cell therapy currently investigated in Phase 3 VIITAL study to treat RDEB.

  • RDEB is a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications.

  • Price Action: ABEO shares are down 4.33% at $1.44 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.